We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


N-of-One Selected by Admera to Provide Clinical Interpretation

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

N-of-One, Inc. has announced that Admera Health has selected N-of-One to provide clinical interpretation of their 64-gene oncology panel, OncoGxOne™. N-of-One’s patient-specific analysis is based on the clinical and scientific evidence linking the results of each patient’s molecular tests to therapeutic strategies, including clinical trials. Financial terms of the agreement are not disclosed.

The OncoGxOne™ is a next-generation sequencing (NGS) panel that detects 64 of the most common mutated genes found in several cancer types. Mutation types detected include single nucleotide variants, insertions and deletions, copy number variants and gene fusions associated with all current FDA approved targeted therapies and multiple registered clinical trials.

Results are delivered in an easy to interpret report providing physicians with the information necessary to practice precision medicine in a cost-efficient manner. N-of-One clinical interpretation provides high-quality analysis of the results of each OncoGxOne™ test, identifying the most relevant therapeutic options for each patient based on the scientific and clinical evidence.

“We are very pleased to be able to offer N-of-One’s patient-specific analysis with our OncoGxOne™ cancer panel,” said James Dermody, Ph.D., Admera Health Lab Director. “Admera Health’s goal of easily integrating into routine clinical practice is supported by partnering with N-of-One. With N-of-One, we can provide oncologists with an Admera Health diagnostic report that is clear, actionable, and based on the latest scientific evidence. We are confident that we can quickly and efficiently provide the very best reports to our customers, so that they can provide the best care possible to their patients.”

“N-of-One is excited to be working with Admera Health to deliver a best-in-class, patient-specific solution to the market,” said Chris Cournoyer, CEO at N-of-One. “Our objective is to continue to provide the highest quality clinical interpretation to enable clinicians to reap the most value from Admera Health’s OncoGxOne™ panel. Ultimately, the patients and their physicians gain the greatest benefit from our working together.”